Newron Pharmaceuticals S.p.A. (SIX: NWRN, XETRA: NP5), a biopharmaceutical company focused on developing novel therapies for central and peripheral nervous system diseases, announced today that its shareholders approved all motions on the agenda for the ordinary part of the Annual General Meeting (AGM) 2026, held today. This included the election of George Garibaldi and Paolo Zocchi as new, independent, and non-executive Board members.
The motions on the agenda for the extraordinary part of the meeting were not put to vote, as the required quorum was not reached. The company did not specify the nature of these extraordinary motions.
Chris Martin, Chairman of the Board of Directors of Newron, expressed gratitude to shareholders for their trust and welcomed the newly elected Board members, stating, “We welcome our newly elected Board members and are looking forward to their valuable inputs.” He also thanked Patrick Langlois and Luca Benatti, who stepped down from the Board after their long-standing service, for their support of Newron.
This development is significant for Newron as it strengthens its board with independent expertise during a critical phase of its lead drug candidate, evenamide. Evenamide is a first-in-class glutamate modulator being developed as a potential add-on therapy for treatment-resistant schizophrenia (TRS) and poorly responding patients with schizophrenia. The drug is currently in the global pivotal ENIGMA-TRS Phase III development program. Clinical trial results to date have shown benefits in TRS and poorly responding patient populations, with significant improvements across key efficacy measures increasing over time, as well as a favorable safety profile uncommon for available antipsychotic medications.
Newron has signed development and commercialization agreements for evenamide with EA Pharma (a subsidiary of Eisai) for Japan and other Asian territories, as well as Myung In Pharm for South Korea. The company’s first marketed product, Xadago®/safinamide, has received marketing authorization for Parkinson’s disease in multiple regions, including the European Union, Switzerland, the UK, the USA, Australia, Canada, Latin America, Israel, the United Arab Emirates, Japan, and South Korea. The product is commercialized by Newron’s partner Zambon, with Supernus Pharmaceuticals holding marketing rights in the U.S., and Meiji Seika responsible for development and commercialization in Japan and other key Asian territories.
The election of independent board members could bring fresh perspectives to Newron’s strategy as it advances its pipeline and navigates regulatory and commercial milestones. The failure to reach quorum for extraordinary motions, however, may indicate that some significant changes or capital measures were deferred. Investors and industry observers will watch for further announcements regarding the company’s plans.
